Skip to main content
PMC home page
Atencion Primaria logoLink to Atencion Primaria
. 2008 Nov 18;38(1):51–57. [Article in Spanish] doi: 10.1157/13090016

Epidemiología de la degeneración macular asociada con la edad. Situación en España

Javier Damián a, Roberto Pastor a, Félix Armadá b, Luis Arias c
PMCID: PMC7676166  PMID: 16790220

The content is available as a PDF (257.4 KB).

Bibliografía

  • 1.Van Leeuwen R., Klaver C.C., Vingerling J.R., Hofman A., De Jong P.T. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol. 2003;121:519–526. doi: 10.1001/archopht.121.4.519. [DOI] [PubMed] [Google Scholar]
  • 2.Slakter J.S., Stur M. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. Surv Ophthalmol. 2005;50:263–273. doi: 10.1016/j.survophthal.2005.02.007. [DOI] [PubMed] [Google Scholar]
  • 3.Casten R.J., Rovner B.W., Tasman W. Age-related macular degeneration and depression: a review of recent research. Curr Opin Ophthalmol. 2004;15:181–183. doi: 10.1097/01.icu.0000120710.35941.3f. [DOI] [PubMed] [Google Scholar]
  • 4.Mangione C.M., Lee P.P., Gutierrez P.R., Spritzer K., Berry S., Hays R.D. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050–1058. doi: 10.1001/archopht.119.7.1050. [DOI] [PubMed] [Google Scholar]
  • 5.World Health Organization Prevention of Blindness & Deafness. Consultation on development of standards for characterization of vision loss and visual functioning. Geneva: WHO/PBL/03.91; 2003.
  • 6.Clemons T.E., Kurinij N., Sperduto R.D. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13. Arch Ophthalmol. 2004;122:716–726. doi: 10.1001/archopht.122.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Buch H., Vinding T., la Cour M., Jensen G.B., Prause J.U., Nielsen N.V. Age-related maculopathy: a risk indicator for poorer survival in women: the Copenhagen City Eye Study. Ophthalmology. 2005;112:305–312. doi: 10.1016/j.ophtha.2004.08.025. [DOI] [PubMed] [Google Scholar]
  • 8.Bird A.C., Bressler N.M., Bressler S.B., Chisholm I.H., Coscas G., Davis M.D. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39:367–374. doi: 10.1016/s0039-6257(05)80092-x. [DOI] [PubMed] [Google Scholar]
  • 9.Van Leeuwen R., Chakravarthy U., Vingerling J.R., Brussee C., Hooghart A.J., Mulder P.G. Grading of age-related maculopathy for epidemiological studies: is digital imaging as good as 35-mm film? Ophthalmology. 2003;110:1540–1544. doi: 10.1016/S0161-6420(03)00501-3. [DOI] [PubMed] [Google Scholar]
  • 10.Klein R., Davis M.D., Magli Y.L., Segal P., Klein B.E., Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology. 1991;98:1128–1134. doi: 10.1016/s0161-6420(91)32186-9. [DOI] [PubMed] [Google Scholar]
  • 11.De Jong P.T. Risk profiles for ageing macular disease. Ophthalmologica. 2004;218(Suppl 1):8–16. doi: 10.1159/000079462. [DOI] [PubMed] [Google Scholar]
  • 12.Klaver C.C., Assink J.J., Van Leeuwen R., Wolfs R.C., Vingerling J.R., Stijnen T. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001;42:2237–2241. [PubMed] [Google Scholar]
  • 13.Klein R., Klein B.E., Linton K.L. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933–943. doi: 10.1016/s0161-6420(92)31871-8. [DOI] [PubMed] [Google Scholar]
  • 14.Mitchell P., Smith W., Attebo K., Wang J.J. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995;102:1450–1460. doi: 10.1016/s0161-6420(95)30846-9. [DOI] [PubMed] [Google Scholar]
  • 15.Vingerling J.R., Dielemans I., Hofman A., Grobbee D.E., Hijmering M., Kramer C.F. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102:205–210. doi: 10.1016/s0161-6420(95)31034-2. [DOI] [PubMed] [Google Scholar]
  • 16.Smith W., Assink J., Klein R., Mitchell P., Klaver C.C., Klein B.E. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108:697–704. doi: 10.1016/s0161-6420(00)00580-7. [DOI] [PubMed] [Google Scholar]
  • 17.Varma R., Fraser-Bell S., Tan S., Klein R., Azen S.P. Prevalence ofage-related macular degeneration in Latinos: the Los Angeles Latino eye study. Ophthalmology. 2004;111:1288–1297. doi: 10.1016/j.ophtha.2004.01.023. [DOI] [PubMed] [Google Scholar]
  • 18.Vannewkirk M.R., Nanjan M.B., Wang J.J., Mitchell P., Taylor H.R., McCarty C.A. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology. 2000;107:1593–1600. doi: 10.1016/s0161-6420(00)00175-5. [DOI] [PubMed] [Google Scholar]
  • 19.Jonasson F., Arnarsson A., Sasaki H., Peto T., Sasaki K., Bird A.C. The prevalence of age-related maculopathy in Iceland: Reykjavik Eye Study. Arch Ophthalmol. 2003;121:379–385. doi: 10.1001/archopht.121.3.379. [DOI] [PubMed] [Google Scholar]
  • 20.Augood C., Fletcher A., Bentham G., Chakravarthy U., De Jong P.T., Rahu M. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol. 2004;11:117–129. doi: 10.1076/opep.11.2.117.28160. [DOI] [PubMed] [Google Scholar]
  • 21.Main results of the EUREYE study. Prevalence of ARM and AMD. London School of Hygiene and Tropical Medicine [accedido 23 Dic 2005]. Disponible en: http://www.lshtm.ac.uk/ncdeu/linktomainresultseureye.html.
  • 22.Serrano-Garijo P., Ramírez-Sebastián J.M. Detección de las alteraciones visuales en el anciano. Rev Esp Geriatr Gerontol. 1991;26:21–28. [Google Scholar]
  • 23.Lago-Bouza J., Ruano-Raviña A., Barros-Dios J., Gómez-Ullade- Irazazábal F. Prevalencia de la degeneración macular asociada a la edad en el área sanitaria de Santiago de Compostela [abstract] Gac Sanit. 2000;14:102. [Google Scholar]
  • 24.Greenland S. Quantitative methods in the review of epidemiologicliterature. Epidemiol Rev. 1987;9:1–30. doi: 10.1093/oxfordjournals.epirev.a036298. [DOI] [PubMed] [Google Scholar]
  • 25.Instituto Nacional de Estadística. Proyecciones de la población Española calcualda a partir del censo de población de 2001. Disponible en: http://www.ine/.es/inebase
  • 26.Tomany S.C., Wang J.J., Van Leeuwen R., Klein R., Mitchell P., Vingerling J.R. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology. 2004;111:1280–1287. doi: 10.1016/j.ophtha.2003.11.010. [DOI] [PubMed] [Google Scholar]
  • 27.Thornton J., Edwards R., Mitchell P., Harrison R.A., Buchan I., Kelly S.P. Smoking and age-related macular degeneration: a review of association. Eye. 2005;19:935–944. doi: 10.1038/sj.eye.6701978. [DOI] [PubMed] [Google Scholar]
  • 28.Seddon J.M., Chen C.A. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin. 2004;44:17–39. doi: 10.1097/00004397-200404440-00004. [DOI] [PubMed] [Google Scholar]
  • 29.Seddon J.M., George S., Rosner B., Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol. 2005;123:774–782. doi: 10.1001/archopht.123.6.774. [DOI] [PubMed] [Google Scholar]
  • 30.Seddon J.M., Gensler G., Milton R.C., Klein M.L., Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA. 2004;291:704–710. doi: 10.1001/jama.291.6.704. [DOI] [PubMed] [Google Scholar]
  • 31.Klein R., Klein B.E., Knudtson M.D., Wong T.Y., Shankar A., Tsai M.Y. Systemic markers of inflammation, endothelial dysfunction, and age-related maculopathy. Am J Ophthalmol. 2005;140:35–44. doi: 10.1016/j.ajo.2005.01.051. [DOI] [PubMed] [Google Scholar]
  • 32.Robman L., Mahdi O., McCarty C., Dimitrov P., Tikellis G., McNeil J. Exposure to Chlamydia pneumoniae Infection and progression of age-related macular degeneration. Am J Epidemiol. 2005;161:1013–1019. doi: 10.1093/aje/kwi130. [DOI] [PubMed] [Google Scholar]
  • 33.Vingerling J.R., Dielemans I., Bots M.L., Hofman A., Grobbee D.E., De Jong P.T. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol. 1995;142:404–409. doi: 10.1093/oxfordjournals.aje.a117648. [DOI] [PubMed] [Google Scholar]
  • 34.McGwin G, Jr, Xie A., Owsley C. The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology. 2005;112:488–494. doi: 10.1016/j.ophtha.2004.10.027. [DOI] [PubMed] [Google Scholar]
  • 35.Guymer R.H., Chiu A.W., Lim L., Baird P.N. HMG CoA Reductase Inhibitors (Statins): Do They Have a Role in Age-related Macular Degeneration? Surv Ophthalmol. 2005;50:194–206. doi: 10.1016/j.survophthal.2004.12.002. [DOI] [PubMed] [Google Scholar]
  • 36.Klein R., Klein B.E. Do statins prevent age-related macular degeneration? Am J Ophthalmol. 2004;137:747–749. doi: 10.1016/j.ajo.2004.01.037. [DOI] [PubMed] [Google Scholar]
  • 37.Haines J.L., Hauser M.A., Schmidt S., Scott W.K., Olson L.M., Gallins P. Complement factor H variant increases the risk ofage-related macular degeneration. Science. 2005;308:419–421. doi: 10.1126/science.1110359. [DOI] [PubMed] [Google Scholar]
  • 38.Edwards A.O., Ritter R., III, Abel K.J., Manning A., Panhuysen C., Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421–424. doi: 10.1126/science.1110189. [DOI] [PubMed] [Google Scholar]
  • 39.Klein R.J., Zeiss C., Chew E.Y., Tsai J.Y., Sackler R.S., Haynes C. Complement factor H polymorphism in age-related maculardegeneration. Science. 2005;308:385–389. doi: 10.1126/science.1109557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Hageman G.S., Anderson D.H., Johnson L.V., Hancox L.S., Taiber A.J., Hardisty L.I. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA. 2005;102:7227–7232. doi: 10.1073/pnas.0501536102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Seddon J.M., Cote J., Page W.F., Aggen S.H., Neale M.C. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol. 2005;123:321–327. doi: 10.1001/archopht.123.3.321. [DOI] [PubMed] [Google Scholar]
  • 42.Gragoudas E.S., Adamis A.P., Cunningham E.T., Jr, Feinsod M., Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816. doi: 10.1056/NEJMoa042760. [DOI] [PubMed] [Google Scholar]
  • 43.A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417-36. [DOI] [PMC free article] [PubMed]
  • 44.Miller E.R., III, Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46. doi: 10.7326/0003-4819-142-1-200501040-00110. [DOI] [PubMed] [Google Scholar]
  • 45.Touvier M., Kesse E., Clavel-Chapelon F., Boutron-Ruault M.C. Dual Association of beta-carotene with risk of tobacco-related cancers in a cohort of French women. J Natl Cancer Inst. 2005;97:1338–1344. doi: 10.1093/jnci/dji276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Taylor H.R., Tikellis G., Robman L.D., McCarty C.A., McNeil J.J. Vitamin E supplementation and macular degeneration: randomized controlled trial. Bmj. 2002;325:11. doi: 10.1136/bmj.325.7354.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Bressler N.M. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract. 2002;15:142–152. [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES